SB-742,457

SB-742,457 is a selective 5-HT6 receptor antagonist with cognition, memory, and learning-enhancing effects. It is currently under development by GlaxoSmithKline for the treatment of Alzheimer's disease and has demonstrated preliminary efficacy in phase II clinical trials.